Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;48(1):52-6.
doi: 10.4068/cmj.2012.48.1.52. Epub 2012 Apr 26.

Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke

Rae Seop Lee  1 , Young Chul Ok, Jun Seob Lim, Byung Chan Lim, Kyu Yong Cho, Min Cheol Lee
Affiliations

Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke

Rae Seop Lee et al. Chonnam Med J. 2012 Apr.

Abstract

The aim of this study was to evaluate the clinical effect of a continuous infusion of urokinase in cerebral stoke patients who were late admitted over 6 hours after onset. From January to December in 2008, acute cerebral stroke patients (n=143) treated with intravenous urokinase infusion (Group I, n=93) or not (Group II, n=50) after 6 hours and within 72 hours of stroke onset were reviewed. Continuous intravenous infusion of urokinase was done for 5 days. The clinical outcome for each patient was evaluated by using the modified National Institutes of Health Stroke Scale (NIHSS) on admission and on the day of discharge. The NIHSS score was decreased at discharge compared with admission in the urokinase treatment group (Group I; from 4.8±2.2 to 3.8±1.9; p=0.002). There was an improvement in the patients who initiated urokinase treatment within 24 hours from stroke onset in Group I (from 5.1±1.9 to 3.9±1.5; p=0.04). In patients with initiated urokinase treatment within 24 hours from stroke onset, intravenous urokinase infusion could be an effective modality in acute ischemic stroke patients admitted later than 6 hours after onset.

Keywords: Brain; Stroke; Urokinase.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Changes in the NIHSS score in the two groups. There was a significant decrease in the NIHSS score at discharge in the urokinase treatment group (Group I). There was no significant difference before and after treatment in Group II. *p<0.05. NIHSS: National Institutes of Health Stroke Scale, Group I: urokinase treatment group, Group II: non-urokinase-treatment group.
FIG. 2
FIG. 2
Changes in the NIHSS score in Group I and Group II according to treatment start time. There was a significant decrease in the NIHSS score in group I with early treatment, no later than 24 hours after onset (6-24 hours). *p<0.05. NIHSS: National Institutes of Health Stroke Scale, Group I: urokinase treatment group, Group II: non-urokinase-treatment group.
See this image and copyright information in PMC

References

    1. Doh WB, Lee BC, Lee IH, Kim SM, Kwon KH. Safety and effect of continuous intravenous urokinase therapy in acute ischemic stroke (Open Clinical Trial) J Korean Neurol Assoc. 1999;17:189–194.
    1. Lee JH, Kim JS, Lee MC, Seo DC, Lee MS. A comparison study on therapeutic efficacy of urokinase vs. heparin in acute ischemic stroke. J Korean Neurol Assoc. 1994;12:225–236.
    1. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275–282. - PubMed
    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587. - PubMed
    1. Chang DI, Yoon SS, Shin WC, Chung KC. Intravenous rt-PA fibrinolytic therapy in acute carotid territory ischemic stroke with severe neurologic deficits: the implication of arterial recanalization for stroke outcome. J Korean Neurol Assoc. 2003;21:1–6.